317 related articles for article (PubMed ID: 15728839)
1. Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.
Akk G; Steinbach JH
J Neurosci; 2005 Feb; 25(8):1992-2001. PubMed ID: 15728839
[TBL] [Abstract][Full Text] [Related]
2. Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.
Ludwig J; Höffle-Maas A; Samochocki M; Luttmann E; Albuquerque EX; Fels G; Maelicke A
J Recept Signal Transduct Res; 2010 Dec; 30(6):469-83. PubMed ID: 21062106
[TBL] [Abstract][Full Text] [Related]
3. Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells.
Storch A; Schrattenholz A; Cooper JC; Abdel Ghani EM; Gutbrod O; Weber KH; Reinhardt S; Lobron C; Hermsen B; Soskiç V
Eur J Pharmacol; 1995 Aug; 290(3):207-19. PubMed ID: 7589215
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.
Roman S; Badia A; Camps P; Muñoz-Torrero D; Clos MV
Brain Res; 2005 Nov; 1061(2):73-9. PubMed ID: 16248990
[TBL] [Abstract][Full Text] [Related]
5. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.
Texidó L; Ros E; Martín-Satué M; López S; Aleu J; Marsal J; Solsona C
Br J Pharmacol; 2005 Jul; 145(5):672-8. PubMed ID: 15834443
[TBL] [Abstract][Full Text] [Related]
6. Competitive potentiation of acetylcholine effects on neuronal nicotinic receptors by acetylcholinesterase-inhibiting drugs.
Zwart R; van Kleef RG; Gotti C; Smulders CJ; Vijverberg HP
J Neurochem; 2000 Dec; 75(6):2492-500. PubMed ID: 11080202
[TBL] [Abstract][Full Text] [Related]
7. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.
Samochocki M; Höffle A; Fehrenbacher A; Jostock R; Ludwig J; Christner C; Radina M; Zerlin M; Ullmer C; Pereira EF; Lübbert H; Albuquerque EX; Maelicke A
J Pharmacol Exp Ther; 2003 Jun; 305(3):1024-36. PubMed ID: 12649296
[TBL] [Abstract][Full Text] [Related]
8. Determinants of phencyclidine potency on the nicotinic acetylcholine receptors from muscle and electric organ.
Eterović VA; Lu R; Eakin AE; Rodríguez AD; Ferchmin PA
Cell Mol Neurobiol; 1999 Dec; 19(6):745-57. PubMed ID: 10456235
[TBL] [Abstract][Full Text] [Related]
9. Topology of ligand binding sites on the nicotinic acetylcholine receptor.
Arias HR
Brain Res Brain Res Rev; 1997 Oct; 25(2):133-91. PubMed ID: 9403137
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
11. Effect of acetylcholinesterase inhibitors on the binding of nicotinic alpha4beta2 receptor PET radiotracer, (18)F-nifene: A measure of acetylcholine competition.
Easwaramoorthy B; Pichika R; Collins D; Potkin SG; Leslie FM; Mukherjee J
Synapse; 2007 Jan; 61(1):29-36. PubMed ID: 17068780
[TBL] [Abstract][Full Text] [Related]
12. Differential pharmacological activity of JN403 between α7 and muscle nicotinic acetylcholine receptors.
Arias HR; De Rosa MJ; Bergé I; Feuerbach D; Bouzat C
Biochemistry; 2013 Nov; 52(47):8480-8. PubMed ID: 24164482
[TBL] [Abstract][Full Text] [Related]
13. Contributions of the non-alpha subunit residues (loop D) to agonist binding and channel gating in the muscle nicotinic acetylcholine receptor.
Akk G
J Physiol; 2002 Nov; 544(3):695-705. PubMed ID: 12411516
[TBL] [Abstract][Full Text] [Related]
14. In vitro galantamine-memantine co-application: mechanism of beneficial action.
Zhao X; Marszalec W; Toth PT; Huang J; Yeh JZ; Narahashi T
Neuropharmacology; 2006 Dec; 51(7-8):1181-91. PubMed ID: 17011596
[TBL] [Abstract][Full Text] [Related]
15. The additional ACh binding site at the α4(+)/α4(-) interface of the (α4β2)2α4 nicotinic ACh receptor contributes to desensitization.
Benallegue N; Mazzaferro S; Alcaino C; Bermudez I
Br J Pharmacol; 2013 Sep; 170(2):304-16. PubMed ID: 23742319
[TBL] [Abstract][Full Text] [Related]
16. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease.
Maelicke A; Samochocki M; Jostock R; Fehrenbacher A; Ludwig J; Albuquerque EX; Zerlin M
Biol Psychiatry; 2001 Feb; 49(3):279-88. PubMed ID: 11230879
[TBL] [Abstract][Full Text] [Related]
17. Activation of α7 nicotinic receptors by orthosteric and allosteric agonists: influence on single-channel kinetics and conductance.
Pałczyńska MM; Jindrichova M; Gibb AJ; Millar NS
Mol Pharmacol; 2012 Nov; 82(5):910-7. PubMed ID: 22874415
[TBL] [Abstract][Full Text] [Related]
18. Galantamine increases excitability of CA1 hippocampal pyramidal neurons.
Oh MM; Wu WW; Power JM; Disterhoft JF
Neuroscience; 2006; 137(1):113-23. PubMed ID: 16242849
[TBL] [Abstract][Full Text] [Related]
19. Binding sites contribute unequally to the gating of mouse nicotinic alpha D200N acetylcholine receptors.
Akk G; Sine S; Auerbach A
J Physiol; 1996 Oct; 496 ( Pt 1)(Pt 1):185-96. PubMed ID: 8910207
[TBL] [Abstract][Full Text] [Related]
20. Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors.
Fletcher GH; Steinbach JH
Mol Pharmacol; 1996 May; 49(5):938-47. PubMed ID: 8622644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
